Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 675, Issue 1-2, 2009, Pages 51-59

  Karapidaki, I ^a,b   Bakopoulou, A ^a   Papageorgiou, A ^c   Iakovidou, Z ^a   Mioglou, E ^a   Nikolaropoulos, S ^d   Mourelatos, D ^a   Lialiaris, T ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c Theagenion Anticancer Institute   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

Antileukemic activity; Caspase 2 and caspase 3 activity; Modified steroidal esters of chlorambucil; Proliferation rate index (PRI); Sister chromatid exchange (SCE)

Indexed keywords

3BETA HYDROXY 17A,AZAHOMOANDROSTAN 7 ONE 4 N,N BIS(2 CHLOROETHYL)AMINOPHENYLACETATE; 3BETA HYDROXY 17BETA ACETAMIDOANDROSTAN 7 ONE 4 N,N BIS(2 CHLOROETHYL)AMINOPHENYLACETATE; 3BETA HYDROXYANDROSTANE 7,17 DIONE 4 N,N BIS(2 CHLOROETHYL)AMINOPHENYLBUTYRATE; ANDROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES CELL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA L 1210; LEUKEMIA P 388; LYMPHOCYTE CULTURE; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PERITONEAL CAVITY; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

ANDROSTERONE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCITES; AZASTEROIDS; CASPASE 2; CASPASE 3; CELL PROLIFERATION; CELLS, CULTURED; CYTOSTATIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; FEMALE; HUMANS; LEUKEMIA L1210; LEUKEMIA P388; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR STRUCTURE; MUTAGENICITY TESTS; NITROGEN MUSTARD COMPOUNDS; SISTER CHROMATID EXCHANGE; STEROIDS; SURVIVAL ANALYSIS;

ANIMALIA; MUS;

EID: 64249086007     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2009.02.010     Document Type: Article

References (51)

1. Hurley L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2 3 (2002) 188-200
2. Kohn K.W. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment-fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 56 24 (1996) 5533-5546
3. Dusenbery K.E., Bellairs E.E., Potish R.A., Twiggs L.B., and Boente M.P. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan: implications for future management of epithelial carcinoma of the ovary. Gynecol. Oncol. 96 2 (2005) 307-313
4. Shamash J., Dancey G., Barlow C., Wilson P., Ansell W., and Oliver R.T. Chlorambucil and iomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br. J. Cancer 92 1 (2005) 36-40
5. Lawley P.D. Alkylation of DNA and its aftermath. Bioassays 17 6 (1995) 561-568
6. Drabløs F., Feyzi E., Aas P.A., Vaagbø C.B., Kavli B., Bratlie M.S., Peña-Diaz J., Otterlei M., Slupphauq G., and Krokan H.E. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst.) 3 11 (2004) 1389-1407
7. Karayianni V., Mioglou E., Iakovidou Z., Mourelatos D., Fousteris M., Koutsourea A., Arsenou E., and Nikolaropoulos S. A new approach for evaluating in vivo anti-leukemic activity using the SCE assay. An application on three newly synthesized anti-tumour steroidal esters. Mutat. Res. 535 1 (2003) 79-86
8. Mourelatos D., Iakovidou Z., Mioglou E., Karapidaki I., Koutsourea A., Arsenou E., Fousteris M., and Nikolaropoulos S. SCEs and PRIs as indicators of structure-biological activity relationship of newly synthesized steroidal esters. Rev. Clin. Pharmakol. Pharmacokinet. 18 (2004) 52-54
9. Carroll F.I., Philip A., Blackwell J.T., Taylor D.J., and Wall M.E. Antitumor and antileukemic effects of some steroids and other biologically interesting compounds containing an alkylating agent. J. Med. Chem. 15 11 (1972) 1158-1161
10. Kasiotis K.M., Magiatis P., Pratsinis H., Skaltsounis A., Abadji V., Charalambous A., Moutsatsou P., and Haroutounian S.A. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids 66 10 (2001) 785-791
11. Kouloumenta A., Stephanou G., Demopoulos N.A., and Nikolaropoulos S.S. Genetic effects caused by potent antileukemic steroidal esters of chlorambucil's active metabolite. Anticancer Drugs 16 1 (2005) 67-75
12. Wasan H., and Waxman J. In: Pusztai L.L., Lewis C.E., and Yap E. (Eds). Cell Proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth (1996), Oxford University Press, Oxford 260-281
13. Lupulescu A.P. Hormones, vitamins and growth factors in cancer treatment and prevention. A critical appraisal. Cancer 78 11 (1996) 2264-2280
14. Arsenou E.S., Fousteris M.A., Koutsourea A.I., Papageorgiou A., Karayianni V., Mioglou E., Iakovidou Z., Mourelatos D., and Nikolaropoulos S.S. The allylic 7-ketone at the steroidal skeleton is crucial for the antileukemic potency of chlorambucil's active metabolite steroidal esters. AntiCancer Drugs 15 10 (2004) 983-990
15. Fousteris M.A., Papageorgiou A., Arsenou E.S., Koutsourea A.I., Karaberis E., Mourelatos D., Onyango D.O., and Nikolaropoulos S.S. Antileukemic and cytogenetic activity by triple administration of three modified steroidal derivatives of nitrogen mustards. Chemotherapy 53 2 (2007) 118-126
16. Deen D.F., Kendall L.E., Marton L.J., and Tofilon P.J. Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay. Cancer Res. 46 4 Pt 1 (1986) 1599-1602
17. Mylonaki-Charalambous E., Mourelatos D., and Kotsis A. A comparative study of the cytogenetic and antineoplastic effects induced by carboplatin in combination with niacin in human lymphocytes in vitro and in Ehrlich ascites tumor cells in vivo. Chemotherapy 44 (1998) 121-128
18. Mourelatos D., Dozi-Vassiliades J., Kotsis A., and Goutsas C. Enhancement of cytogenetic damage and of antineoplastic effect by caffeine in Ehrlich ascites tumor cells treated with cyclophosphamide in vivo. Cancer Res. 48 5 (1988) 1129-1131
19. Tofilon P.J., Basic I., and Milas L. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay. Cancer Res. 45 5 (1985) 2025-2030
20. Camoutsis C., Catsoulacos D., Karayianni V., Papageorgiou A., Mourelatos D., Mioglou E., Kritsi Z., and Nikolaropoulos S. Comparative study of sister chromatid exchange induction and anti-tumor effects by homo-aza-steroidal esters of {p-[bis(2-chloroethyl)amino]phenyl}butyric acid. Cancer Detect. Prev. 25 6 (2001) 558-564
21. Goldin A., Sofina Z., and Syrkin A. Experimental evaluation of antitumor drugs in the U.S.A. and U.S.S.R. and clinical correlations. Natl. Cancer Inst. Monogr. 55 (1980) 25-26
22. Koutsourea A.I., Fousteris M.A., Arsenou E.S., Papageorgiou A., Pairas G.N., and Nikolaropoulos S.S. Synthesis, in vivo antileukemic evaluation and comparative study of novel 5alpha-7-keto steroidal esters of chlorambucil and its active metabolite. In Vivo 22 3 (2008) 345-352
23. Goto K., Maeda S., Kano Y., and Sugiyama T. Factors involved in differential giemsa-staining of sister chromatids. Chromosoma 66 4 (1978) 351-359
24. Noble P.B., Cutts J.H., and Carroll K.K. Ficoll flotation for the separation of blood leukocyte types. Blood 31 1 (1968) 66-73
25. Talanian R.V., Quinlan C., Trautz S., Hackett M.C., Mankovich J.A., Banach D., Ghayur T., Brady K.D., and Wong W.W. Substrate specificities of caspase family proteases. J. Biol. Chem. 272 15 (1997) 9677-9682
26. Carcia-Calvo M., Peterson E.P., Leiting B., Ruel R., Nicholson D.W., and Thornberry N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273 49 (1998) 32608-32613
27. Zhivotovsky B., and Orrenius S. Caspase-2 function in response to DNA damage. Biochem. Biophys. Res. Commun. 331 3 (2005) 859-867
28. Papageorgiou A., Koutsourea A.I., Arsenou E.S., Fousteris M.A., Mourelatos D., and Nikolaropoulos S.S. Structure-anti-leukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil's active metabolite. Anticancer Drugs 16 10 (2005) 1075-1082
29. Mourelatos D. Chromosomes study as predictor of chemoresponse of tumours. Cancer J. 9 3 (1996) 136-141
30. Catsoulacos P., Politis D., and Wampler G.L. A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother. Pharmacol. 3 1 (1979) 67-70
31. Hartley J.A., Berardini M.D., and Souhami R.L. An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and 'second arm' crosslink reactions. Anal. Biochem. 193 1 (1991) 131-134
32. Bank B.B., Kanganis D., Liebes L.F., and Silber R. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Cancer Res. 49 3 (1989) 554-559
33. Lawley P.D., and Brookes P. Interstrand cross-linking of DNA by bifunctional alkylating agents. J. Mol. Biol. 25 1 (1967) 143-160
34. Shafer D.A. Replication bypass model of sister chromatid exchanges and implications for Bloom's syndrome and Fanconi's anemia. Hum. Genet. 39 2 (1977) 177-190
35. Kano Y., and Fujiwara Y. Higher inductions of twin and single sister chromatid exchanges by cross-linking agents in Fanconi's anemia cells. Hum. Genet. 60 3 (1982) 233-238
36. Petrou C., Mourelatos D., Mioglou E., Dozi-Vassiliades J., and Catsoulacos P. Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity and NAD levels in human lymphocytes in vitro and on Ehrlich ascites tumor cells in vivo. Teratog. Carcinog. Mutagen. 10 4 (1990) 321-331
37. Decker P., and Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol. 3 3 (2002) 275-283
38. Kyle S., Thomas H.D., Mitchell J., and Curtin N.J. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. Br. J. Radiol. 81 1 (2008) 6-11
39. Roberts J.J., Brent T.P., and Crathorn A.R. Evidence for the inactivation and repair of the mammalian DNA template after alkylation by mustard gas and half mustard gas. Eur. J. Cancer 7 6 (1971) 515-524
40. Painter R.B. Effect of caffeine on DNA synthesis in irradiated and unirradiated mammalian cells. J. Mol. Biol. 143 3 (1980) 289-301
41. Kohn K.W. Biological aspects of DNA damage by crosslink agents. In: Neidle S., and Waring M.J. (Eds). Molecular Aspects of Anti-Cancer Drug Action (1983) pp. 315-361
42. Salvesen G.S., and Dixit V.M. Caspases: intracellular signalling by proteolysis. Cell 91 4 (1997) 443-446
43. Fan T.J., Han L.H., Cong R.S., and Liang J. Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. 37 11 (2005) 719-727
44. Mancini M., Machamer C.E., Roy S., Nicholson D.W., Thornberry N.A., Casciola- Rosen L.A., and Rosen A. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J. Cell Biol. 149 3 (2000) 603-612
45. Zhivotovsky B., Samali A., Gahm A., and Orrenius S. Caspases: their intracellular localization and translocation during apoptosis. Cell Death Differ. 6 7 (1999) 644-651
46. Lassus P., Opitz-Araya X., and Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297 5585 (2002) 1352-1354
47. Guo Y., Srinivasula S.M., Druilhe A., Fernandes-Alnemri T., and Alnemri E.S. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem. 277 16 (2002) 13430-13437
48. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N., Prévost M.C., Alzari P.M., and Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189 2 (1999) 381-393
49. Wiencke J.K., Wrensch M.R., Miike R., and Petrakis N.L. Individual susceptibility to induced chromosome damage and its implications for detecting genotoxic exposures in human populations. Cancer Res. 51 19 (1991) 5266-5269
50. Hagmar L., Strömberg U., Tinnerberg H., and Mikoczy Z. The usefulness of cytogenetic biomarkers as intermediate endpoints in carcinogenesis. Int. J. Hyg. Environ. Health 204 1 (2001) 43-47
51. Conner M.K., and Wald N. Chromosomal methods in population studies. Environ. Health Perspect. 42 (1981) 107-113